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Abstract. Interleukin-15 (IL-15) has important anabolic 
effects on muscle protein metabolism through a decrease in 
the ATP-ubiquitin-dependent proteolytic pathway. The role of 
IL-15 in human cancer cachexia is unknown. The aim of this 
study was to assess the relationship between interleukin-15 
(IL-15) in cancer patients with cachexia at diagnosis of 
malignancy and 8 weeks later. An observational study of 21 
cancer patients (with and without cachexia) and 8 healthy 
subjects was conducted. Body composition was measured by 
leg-to-leg impedance. Serum IL-15 levels were assessed at 
baseline and after 4 and 8 weeks. Baseline IL-15 values were 
similar in cancer patients and in healthy subjects. Cancer 
patients with lower baseline  levels of IL-15 (<2 pg/ml) had 
significantly higher fat mass (%) along the study. Eighteen 
patients completed the study: five patients showed an increase 
of 3.7 kg at the end of the study (5.4% of body weight) and 
showed a mean increase of IL-15 of 1.32 pg/ml (121%) at 4 
weeks and 2.32 pg/ml (197%) at 8 weeks, as compared with 
mean decrease of -4.1 kg (-5.3%) and -0.09 pg/ml (-2.5%) and 
0.6 pg/ml (40.8%) in the 13 patients who lost weight (P=0.001 
and P=0.022, respectively). Changes of IL-15 at 4 and 8 weeks 
were directly associated with changes in body weight, body 
mass index (BMI), fat-free mass and muscle mass (P<0.05), 
and indirectly associated with percentage of weight loss 
(P<0.05). In summary, although the results indicate that IL-15 
does not have a role in cancer cachexia pathogenesis, the asso-
ciation during evolution between serum IL-15 and changes in 
weight and muscle mass suggests a possible role of IL-15 as a 
marker of the body composition response in cancer patients 
who are losing weight at the time of diagnosis.
Introduction
Cancer-associated cachexia in addition to producing intense 
anorexia, asthenia, and anemia is characterized by weight loss 
and loss of skeletal muscle mass with or without loss of fat 
mass (1-4). Cancer cachexia is a multidimensional and multi-
factorial syndrome, the underlying pathophysiology of which 
is complex and incompletely defined. Although the prevalence 
of cancer cachexia varies by tumor type, it occurs in 15-40% 
of all cancer patients at the time of diagnosis and in 60-80% of 
patients with advanced disease (5). The presence of cachexia 
is associated with deterioration in the quality of life, decreased 
functioning, and higher mortality. It is thought that in cancer, 
>30% of patients die due to cachexia and >50% of patients 
with cancer die with cachexia being present (6).
Interleukin-15 (IL-15) is a multifunctional cytokine 
originally identified in media conditioned by a monkey kidney 
epithelial cell line (CV-1/EBNA) (7). IL-15 induces prolifera-
tion of T cells (8) and shares many biological activities with 
IL-2 since its functions are mediated through the β and γ 
chains of the IL-2 receptor (9). However, unlike IL-2, which 
is produced almost exclusively by activated T cells, the IL-15 
gene is not expressed in these cells, but rather IL-15 mRNA 
has been detected in placenta, skeletal muscle, kidney, lung 
and heart (7). IL-15 can stimulate differentiated myocytes and 
muscle fibres to accumulate increased amounts of contractile 
proteins, suggesting that IL-15 may play a role in skeletal 
muscle fibre growth (10). In cultured skeletal myogenic cells, 
IL-15 action is distinct from insulin-like growth factor-I 
(IGF-I). Overexpression of IL-15 induces hypertrophy of 
skeletal muscle through stimulation of protein synthesis 
and inhibition of protein degradation (11). In a rat model of 
cancer cachexia, IL-15 antagonizes muscle protein waste by 
decreasing protein degradative rates without affecting protein 
synthesis. These anabolic effects of IL-15 were associated 
with an inhibition of the ATP-ubiquitin-dependent proteo-
lytic pathway (12). Moreover, IL-15 was able to suppress the 
increased DNA fragmentation and to suppress several apop-
tosis pathways, including tumor necrosis factor-α (TNF-α) 
signaling pathway and reduction of inducible nitric oxide 
synthase (iNOS) responsible for the synthesis of nitric oxide 
(NO) (13,14). These observations support the anabolic effect 
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of IL-15 on skeletal muscle. For these reasons, and given that 
expression of mRNA is encoded by the IL-15 gene in skeletal 
muscle is increased in cancer, it has been postulated that IL-15 
may act as an anti-cachexia cytokine preserving muscle mass 
and weight loss in animals bearing an experimental model of 
cachexia (15).
Increased protein degradation rates in skeletal muscles are 
associated with muscle wasting in cancer patients, and inhibi-
tion of protein degradation induced by IL-15 may contribute 
to preserve muscle mass in cancer patients with cachexia. The 
objective of this study was to assess the role of IL-15 in cancer 
patients with cachexia at diagnosis of malignancy and during 
the course of the disease.
Subjects and methods
Study population. Between November 2008 and September 
2009, an observational study was performed in cancer patients 
attended in the Service of Oncology of Hospital Universitario 
La Paz in Madrid, Spain. At the time of diagnosis of malig-
nancy, patients were divided into those with cachexia and 
those without cachexia. Patients were included in the group 
with cachexia if they had lost ≥10% of their preillness stable 
weight during the previous 6 months, serum C-reactive protein 
(PCR) ≥10 mg/l, and caloric ingestion of ≤1,500 kcal a day 
in a 72-h nutritional survey. All patients aged between 18 
and 65 years were included in the study. A life expectancy 
>8 weeks was also required as well as a recent diagnosis of 
oncologic disease and no previous cancer therapy except for 
palliative treatment of pain. The study was approved by the 
Ethics Committee of the hospital. Written informed consent 
was obtained from all patients.
Exclusion criteria were as follows: life expectancy <8 
weeks; current nutritional treatment or weight loss diet; 
swallowing difficulty or partial or complete obstruction due 
to a digestive tract tumor; diabetes mellitus; acute or chronic 
inflammatory disease; any type of chronic disease associated 
with the development of cachexia [such as, congestive heart 
failure, severe chronic obstructive pulmonary disease (COPD), 
advanced chronic renal failure, human immunodeficiency 
virus (HIV-1) infection, endocrine disorders]; diseases causing 
malnutrition or malabsorption; acute infections; carriers of 
pacemakers; and patients with moderate-severe depression, 
substance use, or psychiatric disorders that were considered 
ineligible by the attending physician.
Also, healthy subjects aged 18-65 years were asked for 
participation in the study. They were retrospectively selected 
among patients with mild health conditions attended in the 
outpatient clinics of the Service of Internal Medicine during 
the year prior to the study. It was tried to select individuals of 
a similar age (±5 years) and gender than cancer patients being 
recruited. Other inclusion criteria were stable weight during 
the previous 6 months, BMI between 20 and 29.9 kg/m2, and 
absence of oncologic history, current nutritional treatment, 
weight loss diet, and acute or chronic inflammatory or infec-
tious disease.
Procedures. Patients were assessed after diagnosis, before 
the commencement of treatment (baseline visit) and at 4 and 
8 weeks later. After the baseline visit, patients were treated 
(surgery, chemotherapy, radiotherapy, or nutritional support) 
according to individual treatment plans of the Service of 
Oncology. At the baseline and subsequent visits the following 
data were recorded: demographics, salient features of medical 
history, oncologic diagnosis, TNM stage, drug treatment, 
Eastern Cooperative Oncology Group (ECOG) performance 
status (16), self-reported duration of weight loss and weight 
loss percentage [self-reported habitual stable weight (in kg) 
- current weight (in kg) divided by habitual weight (in kg) x 
100]. Weight and height were adjusted to the nearest 0.1 kg 
and 0.01 cm using a calibrated scale (Seca 780, Vogel & Halke 
GmbH & Co., Hamburg, Germany).
At each visit, a physical examination was performed and 
body composition was measured by bioelectrical impedance 
(leg-to-leg impedance) using the Tanita body fat analyzer 
(model BC-420MA, Biologica Tecnologia Medica, S.L., 
Barcelona, Spain) following the protocol described by Utter 
et al (17). Dietary data for the previous 72 h were collected. 
Patients were assessed for appetite according to response to 
the question ‘How do you assess your current level of appe-
tite?’ using a 100-mm visual analog scale (VAS). Asthenia was 
evaluated according to a validated linear analog cancer scale 
developed by the Asthenos Group (18), based on responses 
to the three questions (‘How would you rate your level of 
energy over the past week?’, ‘How would you rate your level 
of ability to perform daily activities over the past week?’ and 
‘How would you rate your quality of life over the past week?’) 
graded from 0 to 100. Muscle function was assessed using 
a Smedley hand grip dynamometer and the treadmill 6-min 
walk test (19).
Laboratory tests. Laboratory tests were carried out at 
baseline and at 4 and 8 weeks, including complete blood 
cell count and standard biochemical profile, inflammatory 
markers (sedimentation rate, serum CRP), thyroid hormones 
(only at the baseline), nutritional markers (serum albumin, 
total proteins, transferrin and total lymphocytes), creatine 
phosphokinase (CPK) and myoglobin. Amino acids were 
measured by high-resolution liquid chromatography using 
Pico-Tag Station (Waters Associates, Milford, MA, USA). 
Baseline insulin levels were measured by a fluoroimmuno-
metric assay (AIA-360 Tosoh Bioscience, San Francisco, CA, 
USA) and serum cortisol by immunofluorescence (Immulite 
2500, Siemens Healthcare Diagnostics, UK). Insulin resis-
tance was detected by the quantitative insulin sensitivity 
check index (QUICKI) (20). Plasma concentrations of IL-15 
and TNF-α receptor II (sTNF-RII) were measured by enzyme 
immunoassay (Quantikine, R&D Systems, Minneapolis, 
MN, USA).
Healthy subjects also attended the three clinical visits and 
underwent the same clinical studies and laboratory tests.
Statistical analysis. Data were analyzed with the SAS 
(version 9.1) statistical software program (SAS Institute, Cary, 
NC, USA). Categorical variables are expressed as frequency 
and percentages, and continuous variables as mean and 
standard deviation (SD) or median and range (minimum, 
maximum) according to the distribution of data. Baseline 
categorical variables were compared with the Fisher's exact 
test and quantitative variables with the Mann-Whitney U 
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test. Two-way analysis of variance (ANOVA) for repeated 
measures with group and time (baseline, week 4, week 8) as 
the two factors was performed. The main effect (mean values 
obtained in each group or mean value at each time point) and 
the interaction between factors (a significant interaction indi-
cated that group profiles were different) was considered. This 
analysis was performed according to the following groups: i) 
percentage of weight loss, ii) baseline IL-15 concentration, and 
iii) net weight loss or weight gain at the end of the study. The 
strength of the association between variables was assessed 
with the Pearson's correlation coefficient. Statistical signifi-
cance was set at P<0.05.
Results
Study subjects. A total of 83 patients with a recent diagnosis 
of cancer were attended during the study period. However, 62 
patients were excluded because of lack of fulfilment of the 
inclusion criteria in 53 and refusal to take part in the study 
in 9. Therefore, the study population included 21 cancer 
patients (90.5% males) with a mean age of 50.2±10.2 years 
(range, 23-65 years). Eight healthy subjects (50% males) with 
a mean age of 47.1±12.9 years were selected. The percentage 
of women was significantly lower among cancer patients than 
among in healthy subjects (9.5 vs. 50%, P=0.033).
Baseline data and serum IL-15 levels. There were 13 cancer 
patients without cachexia (group A) and 8 with cachexia 
(group B). In group A, one patient with pancreatic cancer died 
in the first week after insertion of a biliary stent and another 
with lung cancer discontinued the study voluntarily before 
week 4. In group B, one patient with cancer of unknown origin 
died at week 6 due to hydropic decompensation and hepatic 
encephalopathy. A total of 11 patients in group A, 7 patients in 
group B, and the 8 health subjects completed the study.
Lung cancer was diagnosed in 13 patients (a patient had a 
maxillofacial neoplasm simultaneously), colorectal cancer in 
3, esophageal cancer in 2, T-cell lymphoma in 1, pancreatic 
cancer in 1, and unknown origin in 1. Stage IV disease was 
diagnosed in 8 patients, stage III in 8, stage II in 4 and stage I 
in 1. ECOG performance status was 0 in 11 patients and 1 in 
the remaining 10. The distribution of patients by tumor site, 
cancer stage, and ECOG grade was similar in groups A and 
B. Clinical characteristics of the study population at baseline 
are shown in Table I. There were statistically significant differ-
ences between cancer patients and healthy subjects in weight 
Table I. Baseline characteristics of cancer patients and healthy controls.
 Cancer patients
 ---------------------------------------------------------------------------------------------------------------------------
 All Group A Group B Healthy
Variable patients (n=21) % WL <10% (n=13) % WL ≥10% (n=8) subjects (n=8)
Age (years) 50.2±10.2 52.1±10.5 47.1±9.5 47.1±12.9
Gender, males (%) 19 (90.5) 11 (84.5) 8 (100) 4 (50)
Weight (kg) 75.1±12.1 75.91±12.9 73.8±11.2 68.9±7.3
Height (m) 1.72±0.06 1.7±0.54 1.75±0.76a 1.66±0.83
Body mass index (kg/m2) 25.3±3.9 26.2±4.4 23.9±2.9 25.2±3.6
Weight loss (%) 7.2±5.4b 3.7±3.5b 12.7±2.4b,c -0.3±2.2
Duration of weight loss (days) 80.1±66.1 58.1±62.8 104.7±64.5 NA
Body composition
  Fat mass (%) 22.2±6.72 24.3±7.4 18.8±3.7a 27.7±8.7
  Fat mass (kg) 16.7±6.4 18.3±7.1 14.1±4.1 18.4±6.1
  Fat-free mass (kg) 58.2±8.7a 57.3±9.4 59.5±7.9a 48.9±10.1
  Muscle mass (kg) 55.2±8.4a 54.3±9 56.6±7.6a 46.4±9.5
Appetite, visual analog scale (mm) 55.6±18.2b 56±20.5a 49.6±14.2b 79.4±15.2
Cancer linear analog scale (mm)
  Energy 54.4±21.5 54.6±23.9 54±18.6 70.6±17.4
  Ability to perform daily activities 68.5±20.3 65.8±22.7 72.7±15.9 76.9±24.1
  Quality of life 56.1±23.3a 60.7±24 48.5±21.3a 78±21.6
Nutritional survey (72-h, Kcal/day) 2142.6±561.7 2097.4±577.9 2194.3±583.7 1874.7±339.2
Muscle tests
  Handgrip dynamometer (kg) 41.6±7.7 41.6±9.3 41.6±4.7 35±10.2
  Treadmill 6-min walk (m) 410.6±87.1 436.3±87.3 368.7±73.44a 473.6±56.8
Data are the mean ± standard deviation unless otherwise stated; NA, not applicable; % WL, % weight loss. aP<0.05 and bP<0.001 as compared 
with healthy subjects; cP<0.01 group A vs. group B.
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loss, body fat mass, fat-free mass, and VAS score for appetite 
and quality of life.
Baseline laboratory data are summarized in Table II. 
In comparison with healthy subjects, cancer patients had 
significantly higher values of serum CRP, sedimentation rate, 
isoleucine, leucine, phenylalanine and glutamic acid, and 
significantly lower values of CPK, albumin, transferrin, histi-
dine and high-density lipoprotein (HDL) cholesterol. Serum 
IL-15 concentrations were similar in cancer patients and 
healthy subjects as well as in cancer patients with and without 
cachexia. In the group of cancer patients, differences in IL-15 
concentrations according to age, gender, cancer site (lung vs. 
gastrointestinal tract), cancer stage, ECOG status, weight or 
BMI subgroups were not observed (data not shown). However, 
in the subgroup of cancer patients with fat mass (FM%) <20% 
(n=8) showed higher values of IL-15 than subgroup of patients 
with FM% ≥30% (n=4): (2.4±0.3 vs. 1.2±0.7 pg/ml, P=0.008). 
At baseline, there was a significant relationship between serum 
IL-15 and sTNF-RII (r=0.619, P=0.004).
Body weight and serum IL-15 levels at 4 and 8 weeks. Treatment 
of the patients included chemotherapy in 13, surgery in 9, and 
Table II. Baseline laboratory data in cancer patients and healthy controls.
 Cancer patients
 ---------------------------------------------------------------------------------------------------------------------------
 All Group A Group B Healthy
Variable patients (n=21) % WL <10% (n=13) % WL ≥10% (n=8) subjects (n=8)
Cytokines and hormones
  IL-15 (pg/ml) 1.89±1.08 1.98±0.99 1.77±1.27 1.75±0.41
  sTNF RII (pg/ml) 3733.1±996.2 3694.3±1026.9 3796.2±1010.1 3091±1061.1
  Basal cortisol (µg/dl) 18.7±8.4 19.8±9.1 16.9±7.2 17.5±4.3
  Basal insulin (µU/ml) 10.9±12.4 12.3±15.5 8.6±4.3 5.4±2.5
  Glucose (mg/dl) 96±14 102.2±15.6 88.4±8.3a 95±6.2
  QUICKI 0.35±0.03 0.35±0.05 0.35±0.02 0.38±0.03
Inflammation and muscle proteins
  CRP (mg/l) 44.3±46.9b 36.4 ± 44.2b 57.1±51.4c 3.2±1.6
  Sedimentation rate (mm) 34.1±24.1c 31.4±22.9c 38.4±27.1d 10±7.4
  Myoglobin (µg/l) 20.8±12.7 22.8±8.3 17.5±17.9a,d 27.1±8.6
  CPK (IU/l) 57.6±32.4b 71.9±28.3d 38.6±29.1a,e 148.9±98.3
Nutritional biochemistry
  Albumin (g/dl) 3.6±0.5e 3.5±0.5d 3.5±0.4c 4.3±0.4
  Transferrin (mg/dl) 212.86±49c 219.4±49.4b 202.2±49.8d 267.6±24.2
  Lymphocytes (cells/mm3) 2083±821 2043±682 2148±1059 2166±593
Essential amino acids (µmol/l) 976.2±151.5 957.3±127.7 1006.8±189.5 941.5±81.9
  Histidine 46.3±11.1d 47.7±10.5 44.1±12.5d 55.4±7.1
  Treonine 119.3±50.4 106.1±35.1d 140.9±65.4 130.7±29.1
  Isoleucine 81.8±15.1d 79.1±9.2 86.1±21.7 69.2±10.8
  Leucine 140.6±21.9d 138.5±23.5 144±20 120.7±17.9
  Phenylalanine 66.9±9c 69.1±9.2c 63.5±8d 55±6.9
  Tryptophan 49.1±11.1 50.7±8 46.4±13 54.6±8.8
Non-essential amino acids (µmol/l) 1802.8±322.8 1724.4±221.7 1930.1±428.5 1748.4±140.3
  Glutamic acid 95.2±32.1b 90.1±29.1b 103.5±36.8b 47.2±10.3
  Serine 119.9±24.8 116±23.8 126.4±26.6 108.2±18.3
  Proline 228.7±98.8 201.9±44.9 272.2±144.6 221.2±90.4
Lipid profile
  Total cholesterol (mg/dl) 180.7±43.8 190.9±50.7 164.1±20.1d 220.4±45.8
  HDL-C 39.5±13.1d 42.2±13.75 34±10.6d 55.6±14.3
  LDL-C 119.9±40.9 127.2±47.3 105.3±19.7 137.5±37.9
  Triglycerides 116.9±41.3 125.1±46.1 100.7±25.4 108.7±70.3
Data are the mean ± standard deviation; % WL, % weight loss; aP<0.05 group A vs. group B; bP<0.001, cP<0.005, dP<0.05, eP<0.01 vs. healthy 
subjects.
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palliative care in 8. All patients received dietary counseling. 
Dietary treatment was recommended to 10 patients. Nine 
patients received nutritional supplements, and one patient in 
group B received postoperative enteral nutrition through the 
nasogastric tube.
Throughout the study, differences in weight or serum IL-15 
concentrations between cancer patients and healthy controls, 
and between groups A and B and healthy controls were not 
significant (Fig. 1).
When cancer patients were divided according to baseline 
IL-15 concentrations <2 pg/ml or ≥2 pg/ml, those with IL-15 
levels <2 pg/ml showed higher values fat mass, albumin, trans-
ferrin and amino acids, and lower values of caloric ingestion, 
sTNF RII, sedimentation rate, and myoglobin throughout the 
study period than patient with IL-15 concentrations ≥2 pg/ml 
(P<0.05) (Fig. 2).
A total of 18 cancer patients (group A, n=11; group B, n=7) 
completed the study. In 13 patients (group A, n=8; group B, 
n=5), the mean weight loss was 4.1±1.2 kg (-5.3%) and in the 
remaining 5 patients (group A, n=3; group B, n=2), the mean 
weight gain was 3.7±1.8 kg (5.4%) as compared with baseline 
(P=0.001). Patients who had gained weight at the end of the 
study showed an increase in serum IL-15 concentrations signif-
icantly higher than patients who had lost weight either at week 
4 [1.32±0.47 pg/ml (121%) vs. -0.09±0.29 pg/ml (-2.5%)] and at 
week 8 [2.32±0.83 pg/ml (197%) vs. 0.6±0.51 pg/ml (40.8%)] 
(P=0.022) (Fig. 3). In the subset of 5 patients with weight gain, 
baseline IL-15 concentrations <2 pg/ml were found in 4 and 
≥2 pg/ml in 1. None of these patients were treated surgically 
as compared with 8 patients with weight loss at the end of the 
study (P=0.036). These patients were treated with a higher 
average of chemotherapy cycles compared with patients with 
weight loss at the end of the study, patients who lost weight 
without surgical treatment and patients who lost weight and 
received surgical treatment (3.6±0.2 vs. 1.5±0.4 vs. 2.2±0.6 vs. 
1.1±0.4 cycles of chemotherapy; P=0.004, P=0.032, P=0.004) 
(Table III).
Two patients with lung cancer who had lost weight at the 
end of the study developed lower limbs edema. Chemotherapy 
or surgical treatment were not associated with an increase in 
total body water (% or kgr).
Serum IL-15 levels and body composition. Serum IL-15 levels 
at 4 and 8 weeks were indirectly associated with percentage 
Figure 1. Body weight (A) and serum IL-15 (B) at 4 and 8 weeks in cancer patients and healthy subjects.
Figure 2. Fat mass (%) at 4 and 8 weeks in cancer patients according to baseline IL-15 levels (<2 vs. ≥2 pg/ml).
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of weight loss: (r=-0.508, P=0.026) and (r=-0.657, P=0.004) 
(Fig. 4). Changes in serum IL-15 levels at 4 and 8 weeks as 
compared with baseline values were directly associated with 
changes in body weight, BMI, fat-free mass, and muscle mass 
(P<0.05) and indirectly with percentage of weight loss (P<0.05) 
(Table IV). Changes at 8 weeks were directly associated with 
percentage of fat mass (r=0.485, P=0.048) and fat mass (in kg) 
(r=0.488, P=0.047) and indirectly with serum CRP (r=-0.508, 
P=0.032), basal cortisol (r=-0.6, P=0.008), and lymphocytes 
(r=-0.542, P=0.02).
Discussion
This study shows that in middle-age adults with newly diag-
nosed cancer and weight loss there was no difference  in serum 
IL-15 levels as compared with healthy subjects. Moreover, 
there was no difference in serum IL-15 levels between groups 
A and B and healthy subjects. However, cancer patients with 
baseline IL-15 concentrations <2 pg/ml showed a better pres-
ervation of fat mass, had a better nutritional status, and greater 
ability to regain weight at the end of the study. Moreover, 
Figure 3. Changes in weight (A) and changes in serum IL-15 (B) among 18 patients who completed the study in relation to weight loss (n=13) or weight gain 
(n=5) at week 8.
Table III. Treatments in 18 cancer patients who completed the study in relation to weight loss or weight gain at week 8.
Variables Weight loss (n=13) (%) Weight gain (n=5) (%) P-value
Chemotherapy, N (%) 8 (61.5) 5 (100) NS
Cycles of chemotherapya 1.54±0.4 3.6±0.2 0.004
Surgery, N (%) 8 (61.5) 0 (0) 0.036
Dietary treatment, N (%) 5 (38.5) 3 (60) NS
Nutritional supplements, N (%) 4 (30.1) 3 (60) NS
Enteral nutrition, N (%) 1 (7.7) 0 (0) NS
Palliative care 6 (46.2) 1 (20) NS
NS, not significant; amean ± standard deviation.
Table IV. Correlations in cancer patients between changes of serum IL-15 concentrations at 4 and 8 weeks as compared with 
baseline, and similar changes in body composition.
Variables Week 4 Week 8
IL-15 and weight (kg) r=0.577, P=0.01 r=0.58, P=0.015
IL-15 and BMI (kg/m2) r=0.575, P=0.01 r=0.575, P=0.0161
IL-15 and % weight loss r=-0.548, P=0.015 r=-0.662, P=0.004
IL-15 and fat-free mass (kg) r=0.514, P=0.029 r=0.535, P=0.027
IL-15 and muscle mass (kg) r=0.517, P=0.023 r=0.541, P=0.025
BMI, body mass index.
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patients who gained weight showed an increase in IL-15 values 
at 4 and 8 weeks as compared with baseline levels as well as 
in comparison with patients who lost weight. The findings 
at baseline, initially, suggest that IL-15 is not implicated in 
the pathogenic mechanisms of cachexia in cancer patients. 
Nevertheless, in the evolution, the increase in IL-15 values in 
patients who gained weight and the direct association observed 
between IL-15 levels, body weight, and muscle mass suggest 
that there is a relation between IL-15 and body composition in 
cancer patients.
We used the criterion of weight loss ≥10% to define 
cachexia (1). The present series includes a heterogeneous 
group of tumors, patients were included at the time of diag-
nosis of cancer, and mean duration of weight loss of about 11 
weeks was shorter than mean duration of 24 weeks reported 
in a previous study (1). For this reason, only 38.1% of cancer 
patients met two of the three criteria of cachexia. Weight loss 
≥10% was the main criterion for differentiating patients with 
and without cachexia since the inflammatory status, level 
of appetite, and caloric intake were similar. For this reason, 
weight loss per se was considered the fundamental criterion of 
cachexia, which is consistent with new definition of cachexia 
that uses weight loss ≥5% as the defining criterion (2,21). 
However, when this new criterion was used, no differences in 
body weight or serum IL-15 levels at baseline and at follow-up 
were observed (data not shown).
In healthy subjects, serum levels of IL-15 found in our study 
are similar than those reported by others (22-28), although 
our subjects were older (22,25,26). In ultralongeval subjects 
(>95 years), concentrations of IL-15 higher than in other age 
groups have been described (25). Lamana et al (29) analysed 
the serum IL-15 levels in 161 healthy subjects. Serum IL-15 
levels did not follow a normal distribution, there was a higher 
frequency of values close o zero, the median serum IL-15 value 
was 0.83 pg/ml and there was no clear circadian rhythm. Also, 
there was no difference in the serum IL-15 values according 
to gender and they did not correlate with age. Serum IL-15 
levels above 20 pg/ml were considered high (90th percentile 
of the healthy population). In cancer patients, no differences 
in baseline IL-15 levels according to the stage or extension 
of the disease have been reported (30,31). In general, baseline 
IL-15 levels in cancer patients and controls published in the 
literature are higher than values observed in the present study 
(30-33).On the other hand, especially elevated mean baseline 
IL-15 concentrations have been reported in patients with hepa-
tocarcinoma infected by the hepatitis C virus (77.4 pg/ml) and 
in patients with mycosis fungoides (94.2 pg/ml) (32,33). In a 
series of patients with recent diagnosis of epidermoid carci-
noma of the head and neck, IL-15 was not detected (34), and 
in 50 patients with non-Hodgkin lymphoma, levels of IL-15 
before bone marrow transplantation were 8.75 pg/ml but IL-15 
levels were undetectable in 27 control subjects (35). These 
differences as compared with our study may be due to the fact 
that these studies were not performed at the time of cancer 
diagnosis (30,32,33,35) and that histology, age of the patients 
(31-33,35), laboratory assay (26), and lower levels of detection 
of IL-15 may be also different (30,32,33,35).
Although, some thresholds of IL-15 levels have been asso-
ciated with higher survival rates in patients with non-Hodgkin 
lymphoma and acute B-cell lymphocytic leukaemia (35,36), 
we found differences in nutritional status and body composi-
tion in cancer patients for a threshold of 2 pg/ml. Kuczynski 
et al (37) analyzed serum IL-15 concentrations in 51 type 1 
diabetic patients. Diabetic patients with higher IL-15 serum 
levels (>6 pg/ml) had higher HbA1c values, but differences 
between diabetic patients varying in IL-15 serum levels in 
BMI, serum CRP levels or lipid profile were not observed. In 
previous studies in healthy subjects, postmenopausal women, 
and dialysis patients increases in IL-15 concentrations were 
unrelated to body composition, muscle mass or muscle 
strength (22,23,27,38,39). However, no comparative clinical 
studies of the relationship of cutpoints of serum IL-15 levels 
with nutritional and body composition parameters in cancer 
patients have been carried out.
IL-15 has an anti-adipose effect by inhibiting lipoprotein 
lipase (LPL) activity and de novo lipogenesis. In vivo models, 
the administration of IL-15 produced a 33% decrease in fat 
tissue with a 20% decrease of circulating triglycerides without 
affecting caloric intake. A direct effect of muscular IL-15 
on adipose tissue (muscle-to-fat endocrine axis) has been 
postulated mediated by the presence in adipose tissue of the 
three subunits of the IL-15 receptor (IL-15R) (40-42). Nielsen 
et al (28) showed a negative association between IL-15 and 
body fat mass, which was independent of the diagnosis of 
diabetes type 2. There were no relationships between IL-15 
and plasma lipids. In our study, cancer patients with baseline 
IL-15 concentrations ≥2 pg/ml showed lower values of fat mass 
throughout the study period. These findings suggest a physio-
pathologic anti-adipose role of IL-15 by inhibiting lipogenesis 
and stimulating fat mass depletion associated to cancer weight 
loss. Moreover, IL-15 could be a marker of inflammatory state 
and fat mass content in cancer patients who lose weight.
In our experience, cancer patients who gained weight at 
the end of the study also showed an increase in IL-15 levels 
at weeks 4 and 8. Increases in body weight were related to an 
increase in muscle mass (64%), whereas cancer patients who 
lose weight, weight loss was related to a decrease in fat mass 
Figure 4. Correlations between serum IL-15 concentrations and percentage 
of weight loss at 4 and 8 weeks in cancer patients.
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(61%). Changes in serum IL-15 levels showed a direct rela-
tionship with changes in body weight, BMI, fat-free mass and 
muscle mass, and an indirect association with the percentage 
of weight loss. The fact that these associations were not found 
in healthy subjects support that these changes are specific of 
cancer patients. These findings are consistent with the anabolic 
effects of IL-15 observed in experimental studies (10-15). 
Comparative studies in humans with cancer and weight loss 
are not currently available. However, chemotherapy is the 
natural treatment of cancer, and cancer patients who gained 
weight at the end of the study also received a higher number 
of cycles of chemotherapy as compared with patients who lost 
weight. Chemotherapy has been associated in patients with 
recurrent ovarian and breast cancer, and metastatic melanoma 
with lymphodepletion. Lymphodepletion in these patients was 
also associated with increased serum levels of the lymphocyte 
homeostatic cytokines IL-17 and IL-15 (43,44). In our study, 
changes in serum IL-15 levels at 8 weeks as compared with 
baseline were indirectly associated with changes in lympho-
cyte count. Furthermore, diagnostic or therapeutic surgery 
cause a delay in the initiation of chemotherapy and produce 
and additional catabolic stress. Consequently, surgery can also 
promote weight loss. In our study, cancer patients who were 
treated surgically lost weight at 8 week and received a lesser 
number of cycles of chemotherapy. Thus, weight gain and 
serum IL-15 increase at the end of the study could be related 
with chemotherapy and absence of surgical treatment in these 
patients. In this way, IL-15 could play a possible role as a 
marker of weight and body composition response to chemo-
therapy in cancer patients and weight loss.
Insulin resistance and hypercortisolism are present in 
cachexia (2,4). Studies in rat isolated skeletal muscles suggest 
that the main mechanism involved in the anabolic effects of 
IL-15 in skeletal muscle relies on a decrease in the proteolytic 
rate (45). In animals models of cancer cachexia, the protective 
effect of IL-15 on skeletal muscle proteolysis was nor medi-
ated by corticosteroids and insulin and was due to inhibition 
of the gene expression of the ATP-ubiquitin-dependent protea-
some system (12). The increase in glucocorticoids in patients 
with cachexia may contribute to proteolysis by stimulation of 
the ubiquitin-dependent proteasome activity and to difficult 
protein synthesis diverting amino acids and oligopeptides to 
hepatic synthesis of acute phase reactants (4). In the present 
study, an association between IL-15 and insulin was not 
observed. During the course of the study, however, cancer 
patients showed significantly higher basal insulin concentra-
tions (P=0.07) and lower insulin sensitivity (P=0.041) than 
healthy subjects (data not shown). Patients who gained weight 
at the end of the study had higher basal cortisol levels than 
patients who lost weight (24.8 vs. 15.7 µg/dl, P=0.043). In these 
patients, a decrease in cortisol levels (-34.6%) and an indirect 
association between IL-15, cortisol, and CRP were observed 
at the end of the study. A direct relationship between IL-15 
and amino acids was not observed. However, patients with 
baseline IL-15 levels <2 pg/ml showed higher values of regula-
tory amino acids (such as histidine, tryptophan, and proline) 
and patients with weight gain at the end of the study showed 
increased concentrations of essential amino acids and leucine 
(P=0.015 and P=0.002, data not shown). The regulatory effect 
of some of these amino acids may also contribute to inhibi-
tion of hepatic autophagy proteolysis (46). Leucine is the main 
branched-chain amino acid that regulates protein synthesis 
in skeletal muscle via insulin-dependent and -independent 
signalling pathway and inhibition of proteasome ubiquitin-
dependent proteolysis system (47). This suggests that weight 
gain in cancer patients is a complex process that does not 
depend upon a single metabolic pathway (48).
Limitations of the study include the small sample size and 
the heterogeneity of patients. We used leg-to-leg impedance, 
which is a validated technique to measure body composition 
and to assess changes during weight loss (49). Patients older 
than 65 years of age were excluded to prevent age-associated 
sarcopenia (2,50). Cancer patients with cachexia as compared 
with healthy subjects showed different body composition at 
baseline for two reasons. Firstly, 50% of healthy subjects were 
women, whereas all cancer patients with cachexia were men. 
Sexual dimorphism in body composition (51) is evident from 
adolescence onwards. Apparently, this has not influenced 
the results because serum baseline IL-15 levels in healthy 
subjects are not influenced by the gender (29). Secondly, cancer 
patients with cachexia as compared with healthy subjects had 
previously a higher weight (84.7 vs. 68.5 kg, P=0.036), with 
increased fat and muscle mass. Since weight loss in cancer 
patients with cachexia is initially at the expense of fat, this 
could also explain the different body composition between 
this group of patients and healthy subjects. The weaknesses 
of the studies that measure cytokine levels and relate them to 
the pathogenesis of diseases have been avoided by measuring 
IL-15 levels at baseline and throughout the evolution of 8 weeks 
(52). In addition, the low serum IL-15 levels found in this study 
are not surprising if we bear in mind that cytokines act in an 
autocrine or paracrine manner with high concentrations at sites 
of release but decrease their concentrations after dilution in 
blood. A short half-life or their binding to molecules may diffi-
cult their detection by immunological methods (52). Further 
research is needed to study muscle IL-15 mRNA and muscle 
IL-15 protein from muscle biopsies, simultaneously with serum 
IL-15 concentrations, in cancer patients who lose weight (28).
In summary, in middle-aged patients with a recent cancer 
diagnosis and weight loss, serum IL-15 levels at baseline 
were not different between cancer patients and healthy 
subjects. Therefore, our results do not exclude the role of 
IL-15 in cancer weight loss (cachexia) physiopathology 
because, during evolution, serum IL-15 levels were indirectly 
associated with percentage of weight loss and directly asso-
ciated with body composition in these patients. It would be 
interesting to investigate the relation between chemotherapy, 
weight changes and serum IL-15 levels before establishing 
the anabolic role (anti-cachexia) and the therapeutic potential 
of this cytokine (53).
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